← Leaderboards
Doris Patricia Molina-Henry
University Of Southern California
$1,926,691
Attributed
$7,087,139
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.8M · FY2024–25$10M$7.5M$5M$2.5M$0
'24
'25
Funding mix
By agency
NIH$7,087,139 · 2
By mechanism
R01$6,467,513 · 1
R61$619,626 · 1
Top collaborators
- Mireille Jacobson2 shared
- Paul S. Aisen1 shared
- Keith A. Johnson1 shared
- Reisa A. Sperling1 shared
Most similar at University Of Southern California
Same institution · by research overlap
- Jennifer A Ailshire$5,776,163
- Arthur W Toga$135,966,223
- Hussein N Yassine$19,354,869
- Elizabeth M Zelinski$4,993,573
- Jinkook Lee$57,547,352
Others in their field
Other Rising Stars on “Alzheimer&Apos”
- Kjetil Bjornevik · Harvard University D/B/A Harvard School Of Public Health$3,280,861
- Yanling Wang · Rush University Medical Center$2,986,919
- William G Mantyh · University Of Minnesota$2,961,521
- Allison Mercedes Caban-Holt · University Of Miami School Of Medicine$2,611,182
- Brian Stephen Appleby · Cleveland Clinic Lerner Com-Cwru$2,482,260
- Noah Ray Johnson · University Of Colorado Denver$2,282,487
Research focus
Alzheimer&AposAmyloid Beta-ProteinFundingImpaired CognitionEthnic OriginDementiaRaceMonoclonal AntibodiesReportingCognitiveFutureAducanumabCostAsianCost ComparisonDependenceClinical TrialsBiological FactorsAccelerationCentral AmericaAmericanBlack RaceAffectBeneficiary
Grant awards (3)
The Ante-Amyloid Treatment of Alzheimer's disease (A3) Trial and Alzheimer Plasma EXtension (APEX) Study$6,467,513
R01 · FY2025 · AG
Cost and Non-Cost Barriers to Use of Novel AD Therapeutics among Older Adults$308,285
R61 · FY2025 · AG
Cost and Non-Cost Barriers to Use of Novel AD Therapeutics among Older Hispanic or Latino Adults$311,341
R61 · FY2024 · AG